Mission Creek Capital Partners Inc. Buys New Shares in Tempus AI, Inc. (NASDAQ:TEM)

Mission Creek Capital Partners Inc. acquired a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 47,755 shares of the company's stock, valued at approximately $1,612,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Operose Advisors LLC purchased a new position in Tempus AI during the fourth quarter worth about $25,000. Farther Finance Advisors LLC bought a new position in shares of Tempus AI in the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC increased its position in shares of Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after acquiring an additional 965 shares during the last quarter. NewEdge Advisors LLC bought a new stake in Tempus AI during the fourth quarter worth $49,000. Finally, First Horizon Advisors Inc. boosted its position in Tempus AI by 207.9% in the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock worth $55,000 after purchasing an additional 1,108 shares during the last quarter. 24.22% of the stock is owned by institutional investors.

Tempus AI Stock Performance

NASDAQ TEM traded up $0.18 on Thursday, hitting $51.85. The stock had a trading volume of 6,340,622 shares, compared to its average volume of 5,706,906. The firm has a 50-day moving average of $48.50 and a 200-day moving average of $50.55. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $91.45.

Analyst Upgrades and Downgrades

TEM has been the subject of several research reports. Wolfe Research lowered shares of Tempus AI from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and issued a $70.00 price objective on shares of Tempus AI in a research note on Thursday, April 24th. TD Cowen restated a "buy" rating and issued a $74.00 target price (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Morgan Stanley lifted their price objective on Tempus AI from $50.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. Finally, William Blair reiterated a "market perform" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Tempus AI presently has a consensus rating of "Moderate Buy" and an average price target of $61.08.

Insider Activity at Tempus AI

In related news, CAO Ryan M. Bartolucci sold 13,770 shares of the company's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $60.00, for a total value of $826,200.00. Following the completion of the transaction, the chief accounting officer now directly owns 57,237 shares in the company, valued at approximately $3,434,220. The trade was a 19.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 3,240,234 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.75, for a total value of $190,363,747.50. Following the sale, the chief executive officer now owns 4,895,589 shares in the company, valued at $287,615,853.75. The trade was a 39.83 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,505,134 shares of company stock valued at $268,609,285. Company insiders own 27.60% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.